Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.41
67.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc
Other Long-Term Assets
Rhythm Pharmaceuticals Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
Other Long-Term Assets
$12.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$8.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
44%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$7.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
23%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$10.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
17%
|
CAGR 10-Years
95%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
70%
|
CAGR 5-Years
34%
|
CAGR 10-Years
31%
|
|
Rhythm Pharmaceuticals Inc
Glance View
Rhythm Pharmaceuticals Inc. emerged with a resolute focus, aiming to transform the landscape for individuals grappling with rare genetic disorders of obesity. Founded on the premise that certain predispositions to obesity are deeply rooted in genetics, Rhythm embarked on a journey to develop treatments that target the melanocortin-4 receptor (MC4R) pathway. This pathway plays a critical role in regulating hunger, energy expenditure, and overall body weight. Their flagship product, Imcivree (setmelanotide), gained approval and marked a significant stride forward for the company. It is specifically designed to address the underlying genetic causes of obesity, offering hope to patients who previously had limited therapeutic options. The business model of Rhythm Pharmaceuticals is patient-centric, grounded in innovation and strategic collaborations. They generate revenue through the commercialization of Imcivree, facilitated by partnerships with healthcare providers and institutions that benefit from the specialized treatment they offer. Additionally, Rhythm actively invests in research and development, continually seeking to expand the applicability of their products to other genetic obesity-related conditions. By maintaining a robust pipeline and leveraging scientific advancements, the company positions itself as a pioneer in addressing an underserved niche, sustainably growing through targeted drug development and market expansion initiatives.
See Also
What is Rhythm Pharmaceuticals Inc's Other Long-Term Assets?
Other Long-Term Assets
12.5m
USD
Based on the financial report for Sep 30, 2024, Rhythm Pharmaceuticals Inc's Other Long-Term Assets amounts to 12.5m USD.
What is Rhythm Pharmaceuticals Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
78%
Over the last year, the Other Long-Term Assets growth was -19%. The average annual Other Long-Term Assets growth rates for Rhythm Pharmaceuticals Inc have been 5% over the past three years , 78% over the past five years .
You don't have any saved screeners yet
